Q2 2026 saw 12.8% revenue growth, strong profitability, and margin expansion, led by pain management and appendage management. Strategic clinical trials and new product launches support future growth, while guidance for 2026 was raised for both revenue and adjusted EBITDA.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.